P21
P21 is an intensely potent neurogenic peptide meticulously reverse-engineered from the human Ciliary Neurotrophic Factor (CNTF). Engineered to easily breach the blood-brain barrier, it isolates the pure neuro-regenerative properties of CNTF while actively discarding its severe appetite-suppression side effects. Heavily utilized in elite cognitive recovery protocols to aggressively reverse traumatic brain injury, aggressively clear amyloid plaques, and spark massive de novo hippocampal neurogenesis.
Quick Stats
Mechanism of Action
P21 is a 21-amino-acid fragment (C-terminal portion) of ciliary neurotrophic factor (CNTF). It was identified through structure-activity relationship studies on CNTF to isolate the neurotrophic and metabolic activity without receptor coupling to the JAK/STAT pathway.
P21 promotes neurogenesis, axonal regeneration, and optic nerve repair in preclinical models. It also has significant effects on hypothalamic energy regulation — animal studies showed marked fat mass reduction, improved insulin sensitivity, and increased energy expenditure without reducing food intake or causing cachexia. The metabolic mechanism involves direct activation of hypothalamic AMPK and changes in neuropeptide Y (NPY) / proopiomelanocortin (POMC) signaling.
Source: PMID: 23877024
Background & History
P21 (P021) emerged from the lab of Khalid Iqbal at the New York State Institute for Basic Research in Developmental Disabilities. The peptide was rationally designed from CNTF's active region to retain neurogenic properties while eliminating the appetite suppression (cachexia) that prevented full CNTF from clinical use. In 3xTg-AD mice (triple transgenic Alzheimer model), P21 reduced tau phosphorylation by 50-60%, increased hippocampal neurogenesis 3-fold, and prevented synaptic loss. These are the most impressive pre-clinical results for any neurogenic peptide targeting Alzheimer pathology.
Research Use Cases
- ✓Neurodegenerative disease research (Alzheimer, Parkinson, TBI)
- ✓Adult hippocampal neurogenesis enhancement
- ✓Cognitive enhancement and memory formation
- ✓Neuroprotection in aging protocols
Dosing Protocol
| Typical Dose | 500-2000 mcg/day (SC or intranasal) |
| Frequency | 1× daily |
| Half-Life | ~2-4 hours (estimated) |
| Common Vial Sizes | 5 mg, 10 mg |
Dosing Protocols
Research Protocol
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 500–2000 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 386 mcg | 964 mcg | 1543 mcg |
| 140 lb(63 kg) | 450 mcg | 1125 mcg | 1800 mcg |
| 160 lb(73 kg) | 521 mcg | 1304 mcg | 2086 mcg |
| 180 lb(82 kg) | 586 mcg | 1464 mcg | 2343 mcg |
| 200 lb(91 kg) | 650 mcg | 1625 mcg | 2600 mcg |
| 220 lb(100 kg) | 714 mcg | 1786 mcg | 2857 mcg |
| 250 lb(113 kg) | 807 mcg | 2018 mcg | 3229 mcg |
💉 For exact syringe units based on your vial concentration, use the P21 Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Neuroprotection / Neural Repair
LowStrong preclinical data for axonal regeneration and optic nerve repair. Human data lacking.
Metabolic / Fat Loss
LowHypothalamic energy regulation effects in animals. No human clinical data.
Reconstitution Example
Safety & Considerations
Research compound. No established human safety data. Use only under medical supervision. Preclinical studies show favorable profile.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Research compound with limited human data. No known drug interactions, but theoretical caution with other neurotrophic agents (overlapping BDNF elevation). Monitor for CNS overstimulation when stacking with multiple nootropics.
Synergies & Common Stacks
P21 drives neurogenesis (new neuron growth) while Semax enhances synaptic plasticity in existing neurons — complementary BDNF/NGF upregulation pathways without mechanistic overlap.
Cortexin provides broad neuropeptide support and membrane stabilization while P21 specifically drives hippocampal neurogenesis — complementary neuroprotective approaches.
Dosing Quick Reference
Frequently Asked Questions
What does P21 do?▼
References
- Sleeman MW et al. “"A CNTF-related peptide receptor modulator promotes fat loss".” Endocrinology (2003). PMID: 12949240
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code